Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy.
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study) / Bassetti, M., Vena, A., Giacobbe, D.R., Falcone, M., Tiseo, G., Giannella, M., Pascale, R., Meschiari, M., Digaetano, M., Oliva, A., Rovelli, C., Carannante, N., Losito, A.R., Carbonara, S., Mariani, M.F., Mastroianni, A., Angarano, G., Tumbarello, M., Tascini, C., Grossi, P., et al.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 7:5(2020), pp. 1-11. [10.1093/ofid/ofaa139]
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
Vena, Antonio;Falcone, Marco;Tiseo, Giusy;Giannella, Maddalena;Oliva, Alessandra;Angarano, Gioacchino;Grossi, Paolo;Mastroianni, Claudio Maria;
2020
Abstract
Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bassetti_Ceftolozane/Tazobactam_2020.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
211.45 kB
Formato
Adobe PDF
|
211.45 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
